Skip to content

Company
Pipeline
For Investors
Contact

Company
Pipeline
For Investors
Contact

Press Releases

Choose Year
Search Press Releases

Found 267 Results

June 7, 2021

Relmada Therapeutics Announces Participation in Goldman Sachs 42nd Annual Global Healthcare Conference

June 1, 2021

Relmada Therapeutics Announces Participation in Jefferies Virtual Healthcare Conference

May 26, 2021

Relmada Therapeutics Announces Oral Poster Presentation on REL-1017 at 2021 American Society of Clinical Psychopharmacology Annual Meeting

May 12, 2021

Relmada Therapeutics Provides Corporate Update and Reports First Quarter 2021 Financial Results

May 6, 2021

Relmada Therapeutics to Report First Quarter 2021 Financial Results and Host Conference Call and Webcast on May 12, 2021

May 1, 2021

Relmada Therapeutics Announces Poster Presentations at the American Psychiatric Association Annual Meeting 2021

April 29, 2021

Relmada Therapeutics Announces Poster Presentations at the 2021 Society of Biological Psychiatry Annual Meeting

April 28, 2021

Relmada Therapeutics Announces Participation in the 7th Annual Truist Securities Life Sciences Summit

April 27, 2021

Relmada Therapeutics Announces Poster Presentation at the American Society for Pharmacology and Experimental Therapeutics Annual Meeting at Experimental Biology 2021

April 1, 2021

Relmada Therapeutics Announces Initiation of Second Pivotal Phase 3 Study of REL-1017 as Adjunctive Treatment for Patients with Major Depressive Disorder

«...10 111213 14 15...»

IR Contact

Brian Ritchie
LifeSci Advisors, LLC

+1 (212) 915-2578
britchie@lifesciadvisors.com

Email Alerts Sign-Up

Email

I accept the Privacy Policy^*

Unsubscribe

Loading...

Company

Pipeline
Overview
NDV-01
Speranolone

For Investors
Summary
News
Events
SEC Filings
Corporate Governance
Stock Information

Contact

info@relmada.com

+1 (786) 629-1376

©2026 Relmada Therapeutics, Inc.

Privacy Policy
Terms of Use

Scroll to Top